StreetInsider.com News Articles

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a payment of $88,000 from distribution partner Hangzhou Dongye Medical Technology Company Ltd (HDMT). Eighty thousand dollars of this payment is the third installment of a $700,000 purchase order the Company received from HDMT earlier this year and the additional $8,000 is a new order for LuViva components. The four LuViva devices and components will be shipped this month and will bring the total number of devices shipped to seven of the 35 devices

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor

Thu, 11 Dec 2025 09:00:00 -0500

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced that on August 14th 2025, it had received a payment of $70,000 from its new distribution partner in China, Hangzhou Dongye Medical Technology Company, Ltd. (HDMT). This is the second scheduled payment in a series of nine payments that will total $700,000 in exchange for LuViva components and services. Thus far a total of $100,000 has been received by GTHP. The $70,000 payment received on August 14th 2025 triggers the shipment of three sets of components to HDMT and

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

Tue, 19 Aug 2025 09:00:00 -0500

Guided Therapeutics completes patient enrollment for FDA trial

Wed, 13 Aug 2025 09:00:43 -0500

Guided Therapeutics Inc. (OTCQB: GTHP) announced it has enrolled enough patients to begin closing its U.S. FDA clinical trial for the LuViva Advanced Cervical Scan device and will start data analysis.

The company enrolled approximately 430 patients across four participating clinics, with all sites reaching their minimum specified quotas. The data analysis phase will include completing external review of biopsy samples, reviewing study case report forms, and performing statistical analysis according to the study protocol.

The pathology analysis aims to determine the number of patients with and without disease to ensure a representative mix of disease types. Once this analysis is completed,

Guided Therapeutics completes patient enrollment for FDA trial

Wed, 13 Aug 2025 09:00:43 -0500

The pathology analysis aims to determine the number of patients with and without disease to ensure a representative mix of disease types. Once this analysis is completed,

Guided Therapeutics completes patient enrollment for FDA trial

Wed, 13 Aug 2025 09:00:43 -0500

The pathology analysis aims to determine the number of patients with and without disease to ensure a representative mix of disease types. Once this analysis is completed,

Guided Therapeutics completes patient enrollment for FDA trial

Wed, 13 Aug 2025 09:00:43 -0500

The pathology analysis aims to determine the number of patients with and without disease to ensure a representative mix of disease types. Once this analysis is completed,

Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial